Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Place Priority on “Mutual Understanding” with Industry: Economic Affairs Chief
October 6, 2017
-
REGULATORY Payers Oppose Price Hikes based on CEA at 1st Joint Meeting: Chuikyo
October 5, 2017
-
BUSINESS Japan Debut of MSD’s Zetia/Lipitor Combo Delayed as Cyberattack Woes Continue
October 4, 2017
-
REGULATORY MHLW Wants to Introduce Conditional Early Approval System This Month: Minister
October 3, 2017
-
REGULATORY (Update) Bayer Told to Improve Practice over ADR Reporting Delays, Gets “Verbal Guidance” for Xarelto Survey Fuss
October 2, 2017
-
REGULATORY MHLW Unveils Planned Framework for Conditional Early Approval Scheme
September 29, 2017
-
REGULATORY MHLW OKs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med, Ibrance and More
September 28, 2017
-
REGULATORY As Complaints of Shortages Grow for Japanese Encephalitis Vaccine, MHLW Plans Centralized Collection/Feedback of Supply-Demand Data for Distributers
September 27, 2017
-
TRENDS Japan’s “NDB” Insurance Claim Database Corroborates Slack SGLT-2 Prescriptions for Older People in FY2015
September 26, 2017
-
BUSINESS Opdivo Gains Nod for Gastric Cancer; Spinraza Now Available for All SMA Patients
September 25, 2017
-
BUSINESS Medipal to Become JCR’s Top Shareholder, Poised to Form JV in US
September 22, 2017
-
BUSINESS CSL Ramping Up Investment for New Product Development, 11% R&D-to-Sales Ratio “Appropriate”: CEO
September 22, 2017
-
REGULATORY Kaketsuken in Talks with “Several Entities” over Possible Biz Transfer: New Chief
September 21, 2017
-
BUSINESS NCC, Top 3 Japan Makers Form Immunotherapy Consortium with Eye on Alternative to PD-1 Inhibitors
September 20, 2017
-
BUSINESS Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race
September 19, 2017
-
BUSINESS Chugai’s On-the-Spot ADR Info Provisioning Tools Well Received by Physicians, Spreading to Other Makers
September 15, 2017
-
REGULATORY With 253 Billion Yen Estimate Out, Chuikyo Members Prod MHLW to Vet Impact of Price Maintenance Premium
September 14, 2017
-
REGULATORY (Update) Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
-
REGULATORY Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
-
ORGANIZATION Industry Wants Continued Dialogue to Keep Price Maintenance Premium in Place: Janssen Japan Chief
September 13, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…